AJOONI

Ajooni Biotech Limited

Listed company · ISIN INE820Y01021 · NSE EQ · FV ₹2
Last price
₹3
-0.91%today
What this company does

Ajooni Biotech Limited is a listed company. It booked ₹63 cr of revenue in its latest quarter (Q1 FY27) and kept 0.7% of sales as profit.

Established in 2010, Ajooni Biotech Limited (Ajooni/ABL) is one of India's leading animal nutrition and animal healthcare solution providers, dedicated to enhancing dairy farm productivity and improving livestock performance through scientifically formulated, high-quality products.
In the report:
44out of 100
Equitytale Health Score
Strained

Healthier than 44% of listed companies we score, on all six measures of filed financials. Each measure is ranked against the 1,201–2,858 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
oversold
RSI (14)
25

At close. Not part of the score.

Profitability & returns17

How much profit it earns on the money it employs

Balance sheet51

How much it owes, and whether earnings cover the interest

Cash quality17

Whether reported profit actually arrives as cash

Growth & consistency93

Whether sales and profit have grown, and how steadily

Valuation32

What today's price implies, against our models or its peers

Governance & risk86

How much of the promoters' stake is pledged, and how much they hold

Is this company doing well?
not investment advice
A mixed picture
Strengths
Makes a profit
Sales up 103% vs last year
No promoter shares pledged
Turns profit into real cash
Watch-outs
! Thin 0.7% net margin
! Profit down 45% vs last year
! Low 1.9% return on equity

What if I invest in AJOONI?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹3 -0.91%
latest close · 2026-09-17
52-wk low ₹342 sessions so far52-wk high ₹4
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio81.8High
LowAverageHigh
P/B ratio1.55Moderate
Below bookModerateHigh
EV / EBITDA20.4High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity1.9%Weak
WeakFairStrong ▸15%
Return on capital4.9%Weak
WeakFairStrong
Net margin0.7%Thin
ThinDecentStrong
EBITDA margin3.1%Thin
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.19Comfortable
LowModerateHigh ▸1
Interest cover2.4×Okay
RiskyOkayStrong ▸5×
Current ratio2.72Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹141 cr
Book value
₹2
EPS
₹0.01
latest quarter
Net debt
₹17 cr
owes more than its cash
Enterprise value
₹159 cr
EBITDA
₹8 cr
annualised
EBIT
₹5 cr
annualised
Operating margin
1.8%
Return on assets
1.4%
Earnings yield
1.22%
P/S
0.56
Sales / share
₹5.9
Tax rate
34.0%
Face value
₹2
Shares
43.2 cr
Working capital
₹47 cr
Current assets
₹74 cr
Current liabilities
₹27 cr
Delivery %
77.4%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2026 report & filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹0₹0, midpoint ₹0

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹63 cr
Other Income₹26.9 L
Total Income₹64 cr
Cost of Materials₹55 cr
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹-39.1 L
Employee Benefit Expense₹1 cr
Finance Costs₹48.2 L
Depreciation & Amortisation₹80.3 L
Other Expenses₹6 cr
Total Expenses₹63 cr
Profit before Tax₹65.4 L
Tax Expense₹22.3 L
Net Profit₹43.2 L
Net margin on total income0.7%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹54 cr84.9%
Employee benefit expense₹1 cr2.2%
Finance costs₹48.2 L0.8%
Depreciation & amortisation₹80.3 L1.3%
Other expenses₹6 cr9.9%
Tax expense₹22.3 L0.3%
Profit for the period₹43.2 L0.7%
Total income ₹64 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue59 cr61 cr63 cr
Total income59 cr62 cr64 cr
Expenses57 cr61 cr63 cr
Profit before tax2 cr1 cr65.4 L
Tax70.9 L17.3 L22.3 L
Net profit (owners' share)2 cr94.7 L43.2 L
Net margin (owners' share, on revenue)2.8%1.6%0.7%
EPS (₹)0.100.050.01
YoY (latest quarter): total income +99.8% · net profit -44.7%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹120 cr
Shareholder equity
₹91 cr
parent shareholders
Total debt
₹18 cr
Cash
₹41.9 L
Cash flow · H1 FY26
Operating
₹14 cr
Investing
₹-12 cr
Financing
₹7 cr
Who owns it · 2026-08-12
No pledge
Promoter
30.5%
Public
69.5%
Promoter stake up 4.1% over the last 12 quarters.
Smart-money activity
Insider trades
Boughtparmjeet Kaur · Promoter Group21.12 L · ₹88.7 L30 Dec 25
BoughtJasjot Singh · Promoters1.00 cr · ₹4.2 cr30 Dec 25
SoldHealthy Biosciences Limited · Promoters1.21 cr · ₹5.1 cr30 Dec 25
Bulk / block deals
SoldANANTHARAMAN JANAKI · NSE10.73 L @ ₹3.577 Sep 26
SoldNEO APEX VENTURE LLP · NSE10.50 L @ ₹8.552 Jan 25
BoughtNEO APEX VENTURE LLP · NSE6.50 L @ ₹8.552 Jan 25
Stake changes
BoughtParmeet Kaur · promoter→ 4.52% · 21.12 L30 Dec 25
BoughtJasjot SIngh · promoter→ 16.81% · 1.00 cr30 Dec 25
BoughtJasjot SIngh · promoter→ 16.81% · 1.00 cr30 Dec 25
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 29 Sep 2025
See the official result
1
TO RECEIVE, CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025, TOGETHER WITH THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREON
Backed by 98% of shareholders other than promotersneeded 50%
36.56 L votes for, 77,123 against
2
TO RE-APPOINT A DIRECTOR IN PLACE OF MR. PARTEK SINGH (DIN: 07864006) WHO RETIRES BY ROTATION IN TERMS OF SECTION 152(6) OF THE COMPANIES ACT, 2013 AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT.
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 50%
37.31 L votes for, 2,073 against
3
TO APPROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH HEALTHY BIOSCIENCES LIMITED
Promoters had a personal stake in this
Backed by 98% of shareholders other than promotersneeded 50%
36.56 L votes for, 77,123 against
4
TO APROVE RELATED PARTY TRANSACTIONS OF THE COMPANY WITH PUNJAB BIOTECHNOLOGY PARK LIMITED
Promoters had a personal stake in this
Backed by 98% of shareholders other than promotersneeded 50%
31.73 L votes for, 77,173 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 6 named members
owning 30.5% between them · as of 2026-08-12
JASJOT SINGH15.98%
HEALTHY BIOSCIENCES LIMITED4.97%
PARMJEET KAUR4.30%
UPNEET KAUR2.42%
ASHMEET KAUR1.75%
ISHNEET KAUR1.11%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹42 cr raised in Jun 2024 by offering new shares to existing shareholders

As of Mar 2026, the company says it has spent 97% of what it set aside, leaving ₹1 cr still to be spent.

To Finance Expenditure towards Acquisition of Land, Site, Development and Other Civil Work.
97%
₹8 cr of ₹8 cr
To Acquire the Plant & Machinery
97%
₹8 cr of ₹9 cr
To part finance the working capital requirement
97%
₹15 cr of ₹16 cr
To meet General corporate purposes.
97%
₹10 cr of ₹11 cr
To meet the expenses of the Issue
originally ₹49.1 L
budget changed
97%
₹46.2 L of ₹47.4 L

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.